FDA Warns Type 2 Diabetes Medications May Cause Severe Joint Pain

Article

Health care professionals advised to discontinue drug regimen when appropriate.

Health care professionals advised to discontinue drug regimen when appropriate.

The FDA recently issued a warning for the type 2 diabetes treatments sitagliptin, saxagliptin, linagliptin, and alogliptin due to severe joint pain experienced by some users.

The joint pain can be severe and disabling, therefore caregivers should monitor these conditions. The FDA issued a new Warning and Precaution about this risk to the labels of all medications within the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors.

DPP-4 inhibitors are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, a condition that can lead to blindness, nerve and kidney damage, and heart disease when left untreated.

Patients who experience joint pain from the medications indicated above should not discontinue their medication. They are advised to contact their treating physician and report the problem to the

FDA’s MedWatch Safety Information and Adverse Event Reporting Program.

Health care professionals are advised to discontinue the medication if it seems appropriate to do so.

Related Videos
Cholesterol diet and healthy food eating nutritional concept with clean fruits in nutritionist's heart dish and patient's blood sugar control record with diabetic measuring tool | Image Credit: Chinnapong - stock.adobe.com
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image Credit: Pixel-Shot | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.